Tobemstomig is a bispecific antibody designed to simultaneously target PD-1 and LAG-3 while preferentially acting on tumor-infiltrating lymphocytes. The study demonstrated enhanced expansion of stem-like CD8 T cells, improved T-cell reinvigoration, and durable antitumor responses compared with monospecific checkpoint blockade. Preclinical efficacy supported the clinical development of this dual checkpoint inhibitor strategy.
Dual PD-1 and LAG-3 blockade expanded stem-like CD8 T cells, enhanced effector T-cell responses, improved tumor control, and generated more durable antitumor immunity than single-agent checkpoint inhibition.
Human PD-1 / Human LAG-3 double Knockin mouse — genOway-developed, syngeneic tumor efficacy model
Immuno-oncology, immune checkpoint inhibition, PD-1 blockade, LAG-3 blockade, stem-like T cells, T-cell exhaustion, bispecific antibodies
Human PD-1 Knockin, Human LAG-3 Knockin, double-humanized checkpoint model, syngeneic tumor challenge, tumor-infiltrating lymphocyte profiling, flow cytometry immune monitoring, CD8 T-cell functional analysis, antitumor efficacy studies
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
